10-QPeriod: Q3 FY2024

CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2024

Filed November 6, 2024For Securities:CVS

Summary

CVS Health Corporation reported a significant decline in net income attributable to CVS Health for the third quarter and first nine months of 2024 compared to the same periods in 2023. This was largely driven by substantial restructuring charges of $1.2 billion in Q3 2024, a substantial increase in health care costs, and the recording of significant premium deficiency reserves, particularly within the Health Care Benefits segment. Total revenues saw a modest increase year-over-year, primarily due to growth in premiums and services, but this was outpaced by rising operating costs and health care expenses. Despite the reported net income decline, the company highlighted positive revenue growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, elevated utilization, especially in Medicare Advantage programs, along with medical cost pressures in the Medicaid business, continue to strain the Health Care Benefits segment, leading to substantial premium deficiency reserves. The company is also navigating ongoing litigation, including significant opioid settlements. Management has initiated an enterprise-wide restructuring plan to improve efficiency and reduce costs, which contributed to the substantial charges in the current quarter.

Financial Highlights

54 data points
Beta

Revenue

$95.43B

44.5% Gross Margin

Net Income

$71.00M

0.1% Net Margin

EPS (Diluted)

$0.07

Total Assets

$252.43B

Cash & Equivalents

$6.88B

Free Cash Flow

-$1.42B

Financial Statements
Beta
Revenue$95.43B
Cost of Revenue$52.95B
Gross Profit$42.48B
Operating Expenses$94.60B
Operating Income$832.00M
Net Income$71.00M
EPS (Basic)$0.07
EPS (Diluted)$0.07
Shares Outstanding (Basic)1.26B
Shares Outstanding (Diluted)1.26B

Key Highlights

  • 1Total revenues increased by 6.3% to $95.4 billion for the three months ended September 30, 2024, and by 4.2% to $275.1 billion for the nine months ended September 30, 2024.
  • 2Net income attributable to CVS Health significantly decreased by 96.2% to $87 million in Q3 2024 and by 52.8% to $2.97 billion for the nine months ended September 30, 2024, compared to the prior year periods.
  • 3The company recorded substantial restructuring charges of $1.2 billion in Q3 2024, primarily related to store impairments, corporate workforce optimization, and other asset impairments.
  • 4Health care costs increased significantly by 39.2% in Q3 2024 and 34.3% for the nine-month period, largely due to increased utilization and the recording of approximately $1.1 billion in premium deficiency reserves.
  • 5The Health Care Benefits segment experienced a notable decline in operating income, reporting an adjusted operating loss of $924 million in Q3 2024 compared to an adjusted operating income of $1.5 billion in the prior year, driven by increased utilization and premium deficiency reserves.
  • 6The company repurchased approximately $3.0 billion of common stock in the first nine months of 2024.
  • 7CVS Health is facing ongoing litigation, including opioid settlements, with a maximum payable amount of approximately $4.3 billion related to opioid remediation.

Frequently Asked Questions

The primary reason for the significant decrease in net income attributable to CVS Health in Q3 2024 was the recording of substantial restructuring charges totaling $1.2 billion. These charges were related to an enterprise-wide restructuring plan that included store impairments, corporate workforce optimization, and other asset impairments.

The Health Care Benefits segment saw a significant decline in performance. For Q3 2024, it reported an adjusted operating loss of $924 million, a sharp decrease from an adjusted operating income of $1.5 billion in Q3 2023. This was driven by increased utilization, particularly in Medicare Advantage programs, and the recording of approximately $1.1 billion in premium deficiency reserves. Higher medical costs in the Medicaid business and the impact of Medicare Advantage star ratings also contributed to the decline.

CVS Health has entered into settlement agreements to resolve substantially all opioid claims against the company by participating states, political subdivisions, and tribes. The maximum amount payable under these settlements is approximately $4.3 billion for opioid remediation, plus $625 million for attorneys' fees and costs, to be paid over 10 years. The company has accrued for these settlements and continues to defend against remaining opioid-related cases.

The company had approximately $6.9 billion in cash and cash equivalents as of September 30, 2024. Net cash provided by operating activities decreased significantly in the first nine months of 2024 compared to the prior year, largely due to an early CMS payment received in the prior year and higher Medicare utilization. In May 2024, the company issued approximately $5.0 billion in senior notes for general corporate purposes. The company's long-term debt ratings were "Baa2" by Moody's and "BBB" by S&P as of September 30, 2024, though their outlooks have recently been changed to 'Negative' and one is under review for downgrade, which could impact future borrowing costs.